EPO and chronic kidney disease: Thirdly, we demonstrated that the progression of the pathophysiology of CKD may be involved in the occurrence and the development of AD, especially from the perspective of the RAS, uremic toxins, erythropoietin (EPO), and extracellular vehicles (EVs).